Eidson v. Medtronic, Inc.
40 F. Supp. 3d 1202
N.D. Cal.2014Background
- Medtronic’s Infuse device (rhBMP-2 + LT Cage) received FDA PMA for limited anterior, single-level L4–S1 use; off-label posterior, multi-level, or without LT Cage use was common and allegedly promoted by Medtronic.
- Plaintiffs Scott & April Bell (surgery 2005) and Richard Eidson (surgery 2008) allege off-label Infuse use caused bone overgrowth and other injuries; they assert Medtronic promoted off‑label use, funded/ghostwrote favorable studies, paid opinion leaders, and underreported adverse events to the FDA.
- Procedurally, the court previously dismissed claims in part (Oct. 3, 2013) and granted leave to amend; Defendants moved under Rule 12(b)(6) to dismiss the amended complaints.
- Central legal themes: MDA express preemption (21 U.S.C. §360k), Buckman implied preemption, whether state-law fraud and failure-to-warn claims survive preemption, adequacy of pleading (Rule 9(b)), and statute-of‑limitations (discovery rule) for the Bells.
- Plaintiffs rely in part on a study (Dr. Carragee) alleging massive underreporting of adverse events to support causation for failure-to‑warn claims based on failure to report.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Are the Bells’ claims time‑barred (discovery rule)? | Bells allege non‑disclosure by surgeon, misleading consent, doctors blamed a "biological phenomenon," and they only suspected Infuse in April 2012 after a TV ad; thus discovery rule delays accrual. | Medtronic argues the Bells were on inquiry notice by corrective surgery (2007) or at least by 2008 media coverage. | Court: Denied dismissal — allegations plausibly plead discovery rule and diligence; inquiry‑notice is a factual issue. |
| Are fraud‑based claims (fraud in inducement, negligent misrepresentation) preempted? | Plaintiffs say claims target deceptive off‑label promotion (fraudulent marketing, ghostwritten studies, KOLs), which violate federal prohibitions on false/misleading promotion and are traditional state torts. | Medtronic argues preemption (express and Buckman implied) or that off‑label promotion is not per se a federal violation. | Court: Denied dismissal — fraud claims based on deceptive off‑label promotion are not expressly or impliedly preempted and satisfy Rule 9(b). |
| Are failure‑to‑warn claims (overpromotion/deceptive off‑label promotion) preempted? | Plaintiffs assert failure‑to‑warn via overpromotion (warnings rendered ineffective) and deceptive off‑label promotion undermining warnings. | Medtronic contends such claims would impose duties beyond PMA labeling and are expressly preempted. | Court: Granted dismissal with prejudice — overpromotion and failure‑to‑warn claims that would impose additional/altered labeling/warning duties are expressly preempted. |
| Do failure‑to‑warn claims based on failure to report adverse events to FDA survive preemption and plead causation? | Plaintiffs allege Medtronic underreported adverse events (Carragee study) and that proper reporting to FDA/MAUDE would have put surgeons on notice and changed surgical choices. | Medtronic argues such claims are preempted or fail to plead a causal link (specific unreported events and timing). | Court: Denied dismissal — following Stengel, failure‑to‑report theories parallel federal duties and are not impliedly preempted; amended complaints plausibly allege causation at pleading stage. |
| Do fraud claims meet Rule 9(b) and reliance requirements? | Plaintiffs contend voluminous particularized allegations (specific articles, named KOLs, promotional schemes) and allege surgeons relied on Medtronic’s representations. | Medtronic argues allegations are generalized, lack specific statements relied on by plaintiffs’ surgeons, and amount to impermissible "fraud‑on‑the‑market." | Court: Denied dismissal — complaints plead particularized facts adequate under Rule 9(b); reliance via physicians as agents is adequately alleged and discovery will flesh specifics. |
Key Cases Cited
- Riegel v. Medtronic, 552 U.S. 312 (2008) (establishes MDA express preemption framework for PMA devices)
- Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341 (2001) (holds fraud‑on‑the‑FDA claims are impliedly preempted)
- Stengel v. Medtronic Inc., 704 F.3d 1224 (9th Cir. 2013) (state failure‑to‑report‑to‑FDA claims can parallel federal duties and escape preemption)
- Perez v. Nidek Co., Ltd., 711 F.3d 1109 (9th Cir. 2013) (distinguishes fraud‑by‑omission claims tied solely to PMA scope and discusses Buckman limits)
- Jolly v. Eli Lilly & Co., 44 Cal.3d 1103 (1988) (California discovery rule accrual principles for latent injuries)
- Fox v. Ethicon Endo‑Surgery, Inc., 35 Cal.4th 797 (2005) (pleading requirements when relying on delayed discovery rule)
- Mirkin v. Wasserman, 5 Cal.4th 1082 (1993) (fraud claims require reliance; third‑party/agent reliance recognized)